机构：[1]Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Dept Nephrol, Clin Med Coll 4, Shenzhen, Guangdong, Peoples R China[2]Shenzhen Univ, Shenzhen Key Lab, Gen Hosp, Shenzhen, Guangdong, Peoples R China[3]Cent South Univ, Dept Gastroenterol, Xiangya Hosp 2, Changsha, Hunan, Peoples R China[4]Guangdong Pharmaceut Univ, Dept Nephrol, Hlth Coll, Guangzhou, Guangdong, Peoples R China[5]Peking Univ, Tradit Chinese Med Dept, Shenzhen Hosp, Shenzhen, Guangdong, Peoples R China
BackgroundRegarding the global coronavirus disease 2019 (COVID)-19 pandemic, kidney clear cell carcinoma (KIRC) has acquired a higher infection probability and may induce fatal complications and death following COVID-19 infection. However, effective treatment strategies remain unavailable. Berberine exhibits significant antiviral and antitumour effects. Thus, this study aimed to provide a promising and reliable therapeutic strategy for clinical decision-making by exploring the therapeutic mechanism of berberine against KIRC/COVID-19. MethodsBased on large-scale data analysis, the target genes, clinical risk, and immune and pharmacological mechanisms of berberine against KIRC/COVID-19 were systematically investigated. ResultsIn total, 1,038 and 12,992 differentially expressed genes (DEGs) of COVID-19 and KIRC, respectively, were verified from Gene Expression Omnibus and The Cancer Genome Atlas databases, respectively, and 489 berberine target genes were obtained from official websites. After intersecting, 26 genes were considered potential berberine therapeutic targets for KIRC/COVID-19. Berberine mechanism of action against KIRC/COVID-19 was revealed by protein-protein interaction, gene ontology, and Kyoto Encyclopedia of Genes and Genomes with terms including protein interaction, cell proliferation, viral carcinogenesis, and the PI3K/Akt signalling pathway. In COVID-19 patients, ACOX1, LRRK2, MMP8, SLC1A3, CPT1A, H2AC11, H4C8, and SLC1A3 were closely related to disease severity, and the general survival of KIRC patients was closely related to ACOX1, APP, CPT1A, PLK1, and TYMS. Additionally, the risk signature accurately and sensitively depicted the overall survival and patient survival status for KIRC. Numerous neutrophils were enriched in the immune system of COVID-19 patients, and the lives of KIRC patients were endangered due to significant immune cell infiltration. Molecular docking studies indicated that berberine binds strongly to target proteins. ConclusionThis study demonstrated berberine as a potential treatment option in pharmacological, immunological, and clinical practice. Moreover, its therapeutic effects may provide potential and reliable treatment options for patients with KIRC/COVID-19.
基金：
This study was supportive by Natural Science Foundation of
Hunan Province (No. 2022JJ40706); Guangdong Provincial High
Level Clinical Key Specialties.
第一作者机构：[1]Guangzhou Univ Chinese Med, Shenzhen Tradit Chinese Med Hosp, Dept Nephrol, Clin Med Coll 4, Shenzhen, Guangdong, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zheng Zhihua,Li Xiushen,Nie Kechao,et al.Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets[J].FRONTIERS IN IMMUNOLOGY.2023,14:doi:10.3389/fimmu.2023.1038651.
APA：
Zheng, Zhihua,Li, Xiushen,Nie, Kechao,Wang, Xiaoyu,Liang, Wencong...&Zheng, Yihou.(2023).Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets.FRONTIERS IN IMMUNOLOGY,14,
MLA：
Zheng, Zhihua,et al."Identification of berberine as a potential therapeutic strategy for kidney clear cell carcinoma and COVID-19 based on analysis of large-scale datasets".FRONTIERS IN IMMUNOLOGY 14.(2023)
医学